HomeAI · summaries
Storia in 4 fonti
FDA places partial hold on Biohaven's ion channel drug
An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety data, Biohaven revealed in an SEC filing.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
FDA places partial hold on Biohaven’s epilepsy drug
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
- ·
investors.com
Biohaven's Ratty Setback; How Xenon Benefits
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.
